Opioid prescription is on the increase

More and more opioids are being prescribed for pain relief in Germany. This is the conclusion arrived at by Ingrid Schubert, Peter Ihle, and Rainer Sabatowski, whose study of a sample of inhabitants of the state of Hesse with health insurance from a large statutory provider is published in the latest issue of Deutsches Ärzteblatt International.

Behind this study lies the intention to improve pain treatment with opioids, particularly for patients with cancer. Prescribing too little results in inadequate alleviation of pain, while supplying too much entails the risk of addiction, especially in patients who do not have cancer.

The proportion of persons in the sample who received opioids increased between 2000 and 2010, and so did the number of daily doses per recipient. 3.7 million inhabitants of Germany received opioids in 2010, a million more than in 2000. The frequency of prescription of WHO step 3 opioids increased—most of all in noncancer patients, in spite of the lack of good evidence for this indication.

The study points to inappropriate provision: Despite the increase in opioid prescription, it cannot be concluded that are receiving in adequate amounts.

More information: Dtsch Arztebl Int 2013; 110(4): 45-51

Provided by Deutsches Aerzteblatt International

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments